Elizabeth Romero, MS, RT(N)(CT),PET, FSNMMI-TS – Director of Research and Medical Affairs

Elizabeth  has over 20 years experience in nuclear medicine and PET research. Prior to joining PharmaLogic she practiced in both clinical and research (pre-clinical and clinical trial) PET capacities having worked at Memorial Sloan Kettering Cancer Center and Columbia University/New York State Psychiatric Institute. Using her experience as a clinical research manager and a technologist Ms. Romero interacts with stakeholders at all levels to identify sites for collaboration when new IND agents and clinical trials arise and also works as the point of contact between the manufacturing site and the end users of new radiopharmaceuticals.  Using her knowledge that  includes IRB and IND assistance, technical proficiency, marketing and billing/reimbursement assistance she educates both the end users as well as the PharmaLogic sales force on new products. Liz holds an Associates degree in Nuclear Medicine Technology, a Bachelors in Business Administration, Graduate Certificate in Clinical Research Management and a Master’s degree in Molecular Imaging and Therapeutics.

Reid Gadziala, PharmD, BCNP – Director of Operations

Reid Gadziala joined PharmaLogic in 2018 with years of experience in both SPECT and PET radiopharmaceutical operations management.  His hands-on approach to operations has allowed him to create cohesive cross-functional teams dedicated to navigating the time sensitive and complex world of nuclear medicine.  As an alumni with a BS in Chemistry from James Madison University and both a PharmD. and MBA from Virginia Commonwealth University, Reid enjoys returning to campus to educate both undergrads and student pharmacists on the excitement of a career in such a young and rapidly expanding field.

David Kroon – Director of Development

David Kroon has over twenty years of experience in the pharmaceutical industry, with over ten years experience in PET radiopharmaceuticals. With previous roles at Lantheus Medical Imaging and GE Healthcare, David has been involved in the setup of more than 50 manufacturing sites in six countries, at all stages of product lifecycles from pre-clinical development, through P1-P3 manufacturing and commercialization. David joined PharmaLogic in 2019 and has a uniquely cross-functional view of product development and support.

Teresia Möller, PhD., MSc. – Associate Director of Radiochemistry and Biomarker Development

Teresia Möller joined PharmaLogic in March 2019.  She has numerous years of experience in commercial radiopharmaceutical GMP manufacturing and research and development environments. Prior to PharmaLogic Dr Möller was a Program Manager at GE Healthcare (GEHC) and managed several alliances and relationships with global pharma companies in disease modifying drug clinical trials in Alzheimer’s and Parkinson’s Disease that utilized PET and SPECT imaging agents to screen subjects. Before joining GEHC, Dr Möller led a team responsible for technical support of radioactive diagnostic imaging products and radioanalytical services at Lantheus Medical Imaging. Teresia’s work in validation assessments, separation of radioisotopes, and novel drug development has led to collaboration with numerous pharmaceutical partners.  Dr. Möller received her PhD. in Radiochemistry from University of Helsinki, Finland.